Compare SVM & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | VIR |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.5B |
| IPO Year | 2005 | 2019 |
| Metric | SVM | VIR |
|---|---|---|
| Price | $9.49 | $9.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.50 | ★ $19.63 |
| AVG Volume (30 Days) | ★ 4.6M | 4.4M |
| Earning Date | 02-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $36.87 | N/A |
| Revenue Next Year | $35.34 | $1,049.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.15 | $4.16 |
| 52 Week High | $14.00 | $10.91 |
| Indicator | SVM | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 56.02 |
| Support Level | $6.15 | $8.67 |
| Resistance Level | $11.48 | $10.29 |
| Average True Range (ATR) | 0.65 | 0.58 |
| MACD | -0.36 | -0.09 |
| Stochastic Oscillator | 14.07 | 42.28 |
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.